| Identification | More | [Name]
Iopromide | [CAS]
73334-07-3 | [Synonyms]
IOPROMIDE
N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-N'-methylbenzene-1,3-dicarboxamide
1,3-benzenedicarboxamide,n,n’-bis(2,3-dihydroxypropyl)-5-((methoxyacetyl)amino
6-triiodo-)-n-methyl-4
shl414c
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methyl-
Ultravist
Ultravist 300
Ultravist 370
ZK 35760
N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-N'-methylbenzene-1,3-dicarboxamide
N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetylamino)-N-methylisophthalamide
N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methyl-1,3-benzenedicarboxamide
Proscope | [EINECS(EC#)]
277-385-9 | [Molecular Formula]
C18H24I3N3O8 | [MDL Number]
MFCD00867924 | [Molecular Weight]
791.11 | [MOL File]
73334-07-3.mol |
| Chemical Properties | Back Directory | [Melting point ]
broad (160?C transition) | [Boiling point ]
840.9±65.0 °C(Predicted) | [density ]
2.173±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
Freely soluble in water and in dimethyl sulfoxide, practically insoluble in ethanol (96 per cent) and in acetone. | [form ]
neat | [pka]
10.62±0.70(Predicted) | [color ]
White to off-white | [Stability:]
Hygroscopic | [Major Application]
clinical | [InChI]
InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29) | [InChIKey]
DGAIEPBNLOQYER-UHFFFAOYSA-N | [SMILES]
C1(C(N(CC(O)CO)C)=O)=C(I)C(NC(COC)=O)=C(I)C(C(NCC(O)CO)=O)=C1I | [CAS DataBase Reference]
73334-07-3(CAS DataBase Reference) | [EPA Substance Registry System]
1,3-Benzenedicarboxamide, N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-N1-methyl- (73334-07-3) |
| Safety Data | Back Directory | [Hazard Codes ]
N | [Risk Statements ]
50/53 | [Safety Statements ]
60-61 | [RIDADR ]
UN 3077 9 / PGIII | [WGK Germany ]
3 | [RTECS ]
CZ2230000 | [HazardClass ]
9 | [HS Code ]
2924296000 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Aquatic Acute 1
Aquatic Chronic 1 | [Toxicity]
LD50 in mice, rats (g iodine/kg body weight): 16.5, 11.4 i.v. (Muetzel) |
| Hazard Information | Back Directory | [Description]
Iopromide is a non-ionic, water-soluble X-ray contrast agent for intravascular administration.1,2 Iopromide can cause acute kidney injury and is used in animal models of contrast-induced nephropathy.3,4 | [Chemical Properties]
White Solid | [Uses]
Contrast molecule | [Uses]
Labelled Iopromide. Nonionic, injectable radio-contrast medium. Diagnostic aid (radiopaque medium). | [Definition]
ChEBI: A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A
ater soluble x-ray contrast agent for intravascular administration. | [Brand name]
Ultravist (Berlex). | [General Description]
Iopromide is a low-osmolar,nonionic monomer with 48% bound iodine content. It is indicatedfor use in angiography, excretory urography, andnumerous CT procedures. | [Side effects]
Most common adverse reactions (>1%) are headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, and abnormal vision.
| [References]
[1] YOUNG-HWAN AHN. The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity.[J]. Journal of Korean Medical Science, 2015, 30 3: 245-251. DOI: 10.3346/jkms.2015.30.3.245
[2] JIN-YONG PARK. A new micro-computed tomography-based high-resolution blood-brain barrier imaging technique to study ischemic stroke.[J]. Stroke, 2014, 45 8: 2480-2484. DOI: 10.1161/strokeaha.114.006297
[3] KAMAL HASSAN Hassan F. Is hypoalbuminemia a prognostic risk factor for contrast-induced nephropathy in peritoneal dialysis patients?[J]. Therapeutics and Clinical Risk Management, 2014, 10: 787-795. DOI: 10.2147/tcrm.s70665
[4] NA WANG. Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying Mechanism.[J]. Medical Science Monitor?: International Medical Journal of Experimental and Clinical Research, 2015: 2886-2892. DOI: 10.12659/msm.895543 |
|
|